Weksler B B, Marcus A J, Jaffe E A
Proc Natl Acad Sci U S A. 1977 Sep;74(9):3922-6. doi: 10.1073/pnas.74.9.3922.
Cultured endothelial cells derived from human umbilical veins or bovine aorta produce a potent inhibitor of platelet aggregation. The inhibitor is synthesized from sodium arachidonate or or prostaglandin endoperoxides by a microsomal enzyme system. Tranylcypromine, a specific antagonist of prostacyclin synthetase, suppresses production of the inhibitor by endothelial cells. The inhibitor, which is ether extractable, has been identified using a two-step thin-layer radiochromatographic procedure and a synthetic prostaglandin I2 standard. With this procedure, we have shown that human and bovine endothelial cells convert sodium [3H]arachidonate to radiolabeled prostaglandin I2 and 6-keto-prostaglandin F1alpha, as wellas prostaglandin E2. Thus, endothelial cells may be non-thrombogenic in vivo because they synthesize and release prostaglandin I2, a potent inhibitor of platelet aggregation.
源自人脐静脉或牛主动脉的培养内皮细胞可产生一种强效血小板聚集抑制剂。该抑制剂由微粒体酶系统从花生四烯酸钠或前列腺素内过氧化物合成。反苯环丙胺是前列环素合成酶的特异性拮抗剂,可抑制内皮细胞产生该抑制剂。这种可被乙醚萃取的抑制剂已通过两步薄层层析放射色谱法和合成前列腺素I2标准品进行了鉴定。通过该方法,我们已表明人和牛内皮细胞可将[3H]花生四烯酸钠转化为放射性标记的前列腺素I2、6-酮-前列腺素F1α以及前列腺素E2。因此,内皮细胞在体内可能是非血栓形成性的,因为它们合成并释放前列腺素I2,一种强效血小板聚集抑制剂。